FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 2791-2802

  Kam, Tae In ^a   Song, Sungmin ^a   Gwon, Youngdae ^a   Park, Hyejin ^a   Yan, Ji Jing ^b   Im, Isak ^c   Choi, Ji Woo ^d   Choi, Tae Yong ^e   Kim, Jeongyeon ^a   Song, Dong Keun ^b   Takai, Toshiyuki ^f   Kim, Yong Chul ^c   Kim, Key Sun ^d   Choi, Se Young ^e   Choi, Sukwoo ^a   Klein, William L ^g   Yuan, Junying ^h   Jung, Yong Keun ^a  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

^e School of Dentistry   (South Korea)

^f TOHOKU UNIVERSITY   (Japan)

^g NORTHWESTERN UNIVERSITY   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CASPASE 12; CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR 1; FC RECEPTOR IIB; OLIGOMER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MEMORY DISORDER; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; CHO CELLS; CRICETINAE; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PEPTIDE FRAGMENTS; PRIMARY CELL CULTURE; RECEPTORS, IGG; SIGNAL TRANSDUCTION; SYNAPSES; TRANSCRIPTIONAL ACTIVATION;

EID: 84879616001     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66827     Document Type: Article

References (56)

1. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631-639. (Pubitemid 39061671)
2. Golde TE, Janus C. Homing in on intracellular Aβ? Neuron. 2005;45(5):639-642.
3. Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med . 2003; 9(7):907-913. (Pubitemid 36889934)
4. Lustbader JW, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304(5669):448-452. (Pubitemid 38495942)
5. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature. 2009;457(7233):1128-1132.
6. Yan SD, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996; 382(6593):685-691. (Pubitemid 26282167)
7. Gimbel DA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30(18):6367-6374.
8. Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature. 2010;466(7308):discussion E4-E5.
9. Balducci C, et al. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010; 107(5):2295-2300.
10. Cissé M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci. 2011;31(29):10427-10431.
11. Song S, et al. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell. 2003; 12(3):553-563. (Pubitemid 37222479)
12. Song S, et al. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity. J Cell Biol. 2008;182(4):675-684.
13. Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol. 2002;14(6):698-704. (Pubitemid 35292415)
14. Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity. Immunology. 2003; 108(3):263-273. (Pubitemid 36332384)
15. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma) RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000; 13(2):277-285.
16. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 1996; 379(6563):346-349. (Pubitemid 26033077)
17. Nakamura K, et al. CD3 and immunoglobulin G Fc receptor regulate cerebellar functions. Mol Cell Biol. 2007;27(14):5128-5134. (Pubitemid 47068287)
18. Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J Neuroimmunol. 1993;48(1):71-79.
19. Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12(2):164-178.
20. Lambert MP, et al. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem. 2001;79(3):595-605. (Pubitemid 33029933)
21. Roberson ED, et al. Reducing endogenous tau ameliorates amyloid- β -induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-754. (Pubitemid 46717684)
22. Olferiev M, Masuda E, Tanaka S, Blank MC, Pricop L. The role of activating protein 1 in the transcriptional regulation of the human FCGR2B promoter mediated by the -343 G? C polymorphism associated with systemic lupus erythematosus. J Biol Chem. 2007; 282(3):1738-1746. (Pubitemid 47076680)
23. Cleary JP, et al. Natural oligomers of the amy-loid- beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79-84. (Pubitemid 41236735)
24. Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416(6880):535-539. (Pubitemid 34288854)
25. Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-842.
26. Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409-421. (Pubitemid 36937044)
27. Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45(5):675-688. (Pubitemid 40320703)
28. Kumar-Singh S, et al. In vitro studies of Flemish, Dutch, and wild-type β- amyloid provide evidence for two-staged neurotoxicity. Neurobiol Dis. 2002;11(2):330-340. (Pubitemid 36135696)
29. Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson EJ. β-Amyloid1-42 induces neuronal death through the p75 neurotrophin receptor. J Neurosci. 2008;28(15):3941-3946.
30. Boyce M, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 2005;307(5711):935-939. (Pubitemid 40229232)
31. Nakagawa T, et al. Caspase-12 mediates endoplas-mic- reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000;403(6765):98-103. (Pubitemid 30038529)
32. Urbanc B, et al. In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A. 2004;101(50):17345-17350. (Pubitemid 39657406)
33. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003;26(4):207-214. (Pubitemid 36412003)
34. Crescenzi O, et al. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem. 2002;269(22):5642-5648. (Pubitemid 35365553)
35. Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human fcgam-ma- receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J . 1999;18(5):1095-1103. (Pubitemid 29110295)
36. Goldsmith EB, Erickson BW, Thompson NL. Synthetic peptides from mouse Fc receptor (MoFc gamma RII) that alter the binding of IgG to MoFc gamma RII. Biochemistry. 1997;36(4):952-959. (Pubitemid 27110977)
37. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid β - peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24(13):3370- 3378. (Pubitemid 38451902)
38. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789-791. (Pubitemid 35231524)
39. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007; 8(2):101-112. (Pubitemid 46432529)
40. Sanchez-Mejia RO, et al. Phospholipase A2 reduction amelioreate cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci . 2008; 11(11):1311-1318.
41. Cissé M, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469(7328):47-52.
42. Britschgi M, Wyss-Coray T. Immune cells may fend off Alzheimer disease. Nat Med. 2007;13(4):408-409.
43. Siffrin V, Brandt AU, Herz J, Zipp F. New insights into adaptive immunity in chronic neuroinflammation. Adv Immunol. 2007;96:1-40. (Pubitemid 350027721)
44. Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci . 2007; 30:153-179. (Pubitemid 47218754)
45. Bertram L, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet . 2008; 83(5):623-632.
46. Kono H, et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet . 2005; 14(19):2881-2892. (Pubitemid 41418793)
47. Shankar GM, et al. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life. Neurobiol Dis. 2009;36(2):293-302.
48. Meilandt WJ, et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009;29(7):1977-1986.
49. Cheng IH, et al. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007; 282(33):23818-23828. (Pubitemid 47328006)
50. Janus C, Chishti MA, Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim Biophys Acta. 2000;1502(1):63-75. (Pubitemid 30433856)
51. Westerman MA, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22(5):1858-1867. (Pubitemid 35386304)
52. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med. 2004;10(11):1190-1192. (Pubitemid 39540434)
53. Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177. (Pubitemid 29327547)
54. Bard F, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916-919. (Pubitemid 30644751)
55. Park H, et al. Neuropathogenic role of adenylate kinase-1 in Aβ - mediated tau phosphorylation via AMPK and GSK3β . Hum Mol Genet . 2012; 21(12):2725-2737.
56. Woo HN. et al. Inhibition of Bcl10-mediated activation of NF-kappa B by BinCARD, a Bcl10-interacting CARD protein. FEBS Lett. 2004;578(3):239-244.